Auna S.A. Announces 2025 Financial Results Dates
- Earnings Release Schedule: Auna S.A. is set to report its Fourth Quarter and Full-Year 2025 financial results on March 10, 2026, after market close, which is expected to provide investors with critical performance data to assess the company's future growth potential.
- Conference Call Timing: The company will hold a conference call on March 11, 2026, at 8:00 a.m. ET to provide a detailed interpretation of the financial results and answer investor questions, thereby enhancing transparency and investor confidence.
- Quiet Period Details: Auna will enter a quiet period from February 23 to March 10, 2026, during which no public discussions related to financial performance will occur, ensuring compliance and fairness in information disclosure.
- Company Background: Auna is a leading healthcare services and plan provider in Latin America, focusing on high-complexity diseases, with a network of 31 healthcare facilities and 2,333 beds, serving 1.4 million healthcare plans, showcasing its strong integration capabilities in the Spanish-speaking markets.
Trade with 70% Backtested Accuracy
Analyst Views on AUNA
About AUNA
About the author
Auna Executes Addendum to PPP Agreement with EsSalud
- Project Milestone: Auna's signing of the addendum with EsSalud formally authorizes the construction of the Torre Trecca project, which is expected to commence operations in mid-2028, significantly enhancing healthcare capacity in metropolitan Lima.
- Service Expansion: Torre Trecca will provide approximately 600,000 patient services in its first operational year, with plans for annual increases, aiming to reduce waiting times for over six million insured Peruvians.
- Infrastructure Investment: The project operates under a 20-year concession framework, with Auna's construction capital expenditures reimbursed by EsSalud through progress certificates, ensuring predictable revenue streams and minimizing financial risk.
- Strategic Market Opportunity: Auna's CEO emphasized that this partnership not only expands its market reach in Peru but also enhances the company's competitiveness in the Latin American healthcare sector by delivering high-quality medical services.
Auna S.A. Announces 2025 Financial Results Dates
- Earnings Release Schedule: Auna S.A. is set to report its Fourth Quarter and Full-Year 2025 financial results on March 10, 2026, after market close, which is expected to provide investors with critical performance data to assess the company's future growth potential.
- Conference Call Timing: The company will hold a conference call on March 11, 2026, at 8:00 a.m. ET to provide a detailed interpretation of the financial results and answer investor questions, thereby enhancing transparency and investor confidence.
- Quiet Period Details: Auna will enter a quiet period from February 23 to March 10, 2026, during which no public discussions related to financial performance will occur, ensuring compliance and fairness in information disclosure.
- Company Background: Auna is a leading healthcare services and plan provider in Latin America, focusing on high-complexity diseases, with a network of 31 healthcare facilities and 2,333 beds, serving 1.4 million healthcare plans, showcasing its strong integration capabilities in the Spanish-speaking markets.
Auna S.A. Announces 2025 Financial Results Dates
- Earnings Release Schedule: Auna S.A. will report its Fourth Quarter and Full-Year 2025 financial results after market close on March 10, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Timing: The company plans to hold a conference call on March 11, 2026, at 8:00 a.m. ET to discuss financial results and address investor inquiries, aiming to enhance market confidence.
- Quiet Period Details: Auna's quiet period will run from February 23 to March 10, 2026, indicating the company's cautious approach to information disclosure prior to earnings release to avoid market misinterpretation.
- Company Background: Auna is a leading healthcare services and plan provider in Latin America, operating 31 healthcare network facilities and managing 1.4 million healthcare plans, focusing on high-complexity diseases, showcasing its strong integration capabilities in the Spanish-speaking markets.
EsSalud Receives Construction License for Torre Trecca, Signifying Important Milestone in Auna's Public-Private Partnership with the Organization
Construction License Received: Auna S.A. has received a construction license for Torre Trecca, a high-rise outpatient treatment center in Lima, Peru, which will serve over six million EsSalud-insured Peruvians.
Public-Private Partnership: The project is part of a public-private partnership with EsSalud, initiated in 2010, aimed at modernizing healthcare services in the region.
Expected Impact: Once completed, Torre Trecca is projected to accommodate more than three million visits annually, significantly enhancing healthcare access in Lima.
Forward-Looking Statements: Auna's announcement includes forward-looking statements regarding the project's timeline and capacity, emphasizing potential risks and uncertainties that may affect outcomes.
Honeywell Analyst Adopts Bearish Stance; Check Out Tuesday's Top 4 Downgrades
Analyst Downgrades: JP Morgan's Hanzade Kilickiran downgraded D-MARKET Electronic from Overweight to Neutral, lowering the price target from $4.85 to $3.07, with shares closing at $2.31.
Federal Realty Investment Trust: Barclays analyst Richard Hightower downgraded Federal Realty Investment Trust from Overweight to Equal-Weight, reducing the price target from $113 to $106, while shares closed at $96.00.
Auna SA: JP Morgan's Joseph Giordano downgraded Auna SA from Overweight to Neutral, cutting the price target from $13.5 to $6, with shares closing at $5.00.
Honeywell International Inc: B of A Securities analyst Andrew Obin downgraded Honeywell from Buy to Underperform, slashing the price target from $265 to $205, as shares closed at $196.08.
Alphabet Set to Surge Over 12%? Check Out 10 Leading Analyst Predictions for Tuesday
Analyst Upgrades and Price Target Increases: HC Wainwright & Co. raised the price target for Zymeworks Inc. from $26 to $32 while maintaining a Buy rating. Jefferies also increased the price target for Legence Corp. from $39 to $49 and upgraded the stock from Hold to Buy.
Analyst Downgrades and Price Target Cuts: BTIG cut the price target for LifeMD Inc. from $18 to $10, while JP Morgan reduced Auna SA's target from $13.5 to $6 and downgraded it from Overweight to Neutral.
Mixed Ratings and Price Adjustments: Canaccord Genuity lowered TELA Bio Inc.'s price target from $7 to $4 but kept a Buy rating, whereas B of A Securities cut Honeywell International Inc.'s target from $265 to $205 and downgraded it from Buy to Underperform.
Other Notable Changes: Loop Capital raised Alphabet Inc.'s price target from $260 to $320 and upgraded it from Hold to Buy, while HC Wainwright & Co. increased HIVE Digital Technologies Ltd.'s target from $8 to $10, maintaining a Buy rating.
Auna Executes Addendum to PPP Agreement with EsSalud
- Project Milestone: Auna's signing of the addendum with EsSalud formally authorizes the construction of the Torre Trecca project, which is expected to commence operations in mid-2028, significantly enhancing healthcare capacity in metropolitan Lima.
- Service Expansion: Torre Trecca will provide approximately 600,000 patient services in its first operational year, with plans for annual increases, aiming to reduce waiting times for over six million insured Peruvians.
- Infrastructure Investment: The project operates under a 20-year concession framework, with Auna's construction capital expenditures reimbursed by EsSalud through progress certificates, ensuring predictable revenue streams and minimizing financial risk.
- Strategic Market Opportunity: Auna's CEO emphasized that this partnership not only expands its market reach in Peru but also enhances the company's competitiveness in the Latin American healthcare sector by delivering high-quality medical services.
Auna S.A. Announces 2025 Financial Results Dates
- Earnings Release Schedule: Auna S.A. is set to report its Fourth Quarter and Full-Year 2025 financial results on March 10, 2026, after market close, which is expected to provide investors with critical performance data to assess the company's future growth potential.
- Conference Call Timing: The company will hold a conference call on March 11, 2026, at 8:00 a.m. ET to provide a detailed interpretation of the financial results and answer investor questions, thereby enhancing transparency and investor confidence.
- Quiet Period Details: Auna will enter a quiet period from February 23 to March 10, 2026, during which no public discussions related to financial performance will occur, ensuring compliance and fairness in information disclosure.
- Company Background: Auna is a leading healthcare services and plan provider in Latin America, focusing on high-complexity diseases, with a network of 31 healthcare facilities and 2,333 beds, serving 1.4 million healthcare plans, showcasing its strong integration capabilities in the Spanish-speaking markets.
Auna S.A. Announces 2025 Financial Results Dates
- Earnings Release Schedule: Auna S.A. will report its Fourth Quarter and Full-Year 2025 financial results after market close on March 10, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Timing: The company plans to hold a conference call on March 11, 2026, at 8:00 a.m. ET to discuss financial results and address investor inquiries, aiming to enhance market confidence.
- Quiet Period Details: Auna's quiet period will run from February 23 to March 10, 2026, indicating the company's cautious approach to information disclosure prior to earnings release to avoid market misinterpretation.
- Company Background: Auna is a leading healthcare services and plan provider in Latin America, operating 31 healthcare network facilities and managing 1.4 million healthcare plans, focusing on high-complexity diseases, showcasing its strong integration capabilities in the Spanish-speaking markets.
EsSalud Receives Construction License for Torre Trecca, Signifying Important Milestone in Auna's Public-Private Partnership with the Organization
Construction License Received: Auna S.A. has received a construction license for Torre Trecca, a high-rise outpatient treatment center in Lima, Peru, which will serve over six million EsSalud-insured Peruvians.
Public-Private Partnership: The project is part of a public-private partnership with EsSalud, initiated in 2010, aimed at modernizing healthcare services in the region.
Expected Impact: Once completed, Torre Trecca is projected to accommodate more than three million visits annually, significantly enhancing healthcare access in Lima.
Forward-Looking Statements: Auna's announcement includes forward-looking statements regarding the project's timeline and capacity, emphasizing potential risks and uncertainties that may affect outcomes.
Honeywell Analyst Adopts Bearish Stance; Check Out Tuesday's Top 4 Downgrades
Analyst Downgrades: JP Morgan's Hanzade Kilickiran downgraded D-MARKET Electronic from Overweight to Neutral, lowering the price target from $4.85 to $3.07, with shares closing at $2.31.
Federal Realty Investment Trust: Barclays analyst Richard Hightower downgraded Federal Realty Investment Trust from Overweight to Equal-Weight, reducing the price target from $113 to $106, while shares closed at $96.00.
Auna SA: JP Morgan's Joseph Giordano downgraded Auna SA from Overweight to Neutral, cutting the price target from $13.5 to $6, with shares closing at $5.00.
Honeywell International Inc: B of A Securities analyst Andrew Obin downgraded Honeywell from Buy to Underperform, slashing the price target from $265 to $205, as shares closed at $196.08.
Alphabet Set to Surge Over 12%? Check Out 10 Leading Analyst Predictions for Tuesday
Analyst Upgrades and Price Target Increases: HC Wainwright & Co. raised the price target for Zymeworks Inc. from $26 to $32 while maintaining a Buy rating. Jefferies also increased the price target for Legence Corp. from $39 to $49 and upgraded the stock from Hold to Buy.
Analyst Downgrades and Price Target Cuts: BTIG cut the price target for LifeMD Inc. from $18 to $10, while JP Morgan reduced Auna SA's target from $13.5 to $6 and downgraded it from Overweight to Neutral.
Mixed Ratings and Price Adjustments: Canaccord Genuity lowered TELA Bio Inc.'s price target from $7 to $4 but kept a Buy rating, whereas B of A Securities cut Honeywell International Inc.'s target from $265 to $205 and downgraded it from Buy to Underperform.
Other Notable Changes: Loop Capital raised Alphabet Inc.'s price target from $260 to $320 and upgraded it from Hold to Buy, while HC Wainwright & Co. increased HIVE Digital Technologies Ltd.'s target from $8 to $10, maintaining a Buy rating.
